Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2011 (2011), Article ID 717951, 6 pages
http://dx.doi.org/10.1155/2011/717951
Review Article

HCV Virus and Lymphoid Neoplasms

1Department of Hematology, Hakodate Municipal Hospital, 1–10-1 Minato-cho, Hakodate 041-8680, Japan
2Department of Clinical Pathology, Hakodate Municipal Hospital, 1–10-1 Minato-cho, Hakodate 041-8680, Japan
3Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo 60-8638, Japan
4Department of Gastroenterology, Hokkaido University Graduate School of Medicine, Sapporo 60-8638, Japan

Received 13 March 2011; Accepted 7 May 2011

Academic Editor: Daisuke Ennishi

Copyright © 2011 Yutaka Tsutsumi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Amin, G. J. Dore, D. O'Connell et al., “Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study,” Journal of Hepatology, vol. 45, no. 2, pp. 197–203, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. R. Strauss, A. Torner, A. S. Duberg et al., “Hepatocellular carcinoma and other primaly liver cancers in hepatitis C patients in Sweeden-a low endemic country,” Journal of Viral Hepatitis, vol. 15, pp. 531–537, 2008. View at Google Scholar
  3. K. Matsuo, A. Kusano, A. Sugumar, K. Tajima, N. Mueller, and S. Nakamura, “Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies,” Cancer Science, vol. 95, no. 9, pp. 745–752, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Schöllkopf, K. E. Smedby, H. Hjalgrim et al., “Hepatitis C infection and risk of malignant lymphoma,” International Journal of Cancer, vol. 122, no. 8, pp. 1885–1890, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. S. Shiratori, Y. Tsutsumi, T. Kawamura et al., “HCV non-structural protein 3 and HCV RNA genome in non-Hodgkin lymphoma and transition of the serum HCV RNA level: a retrospective analysis in one institution,” International Journal of Hematology, vol. 87, no. 3, pp. 298–302, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. Y. Tsutsumi, K. Ichiki, S. Shiratori et al., “Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin's lymphoma patients after rituximab chemotherapy,” International Journal of Laboratory Hematology, vol. 31, no. 4, pp. 468–470, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. L. Dal Maso and S. Franceschi, “Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 11, pp. 2078–2085, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. C. Ferri, F. Caracciolo, A. L. Zignego et al., “Hepatitis C virus infection in patients with non-Hodgkin's lymphoma,” British Journal of Haematology, vol. 88, no. 2, pp. 392–394, 1994. View at Google Scholar · View at Scopus
  9. G. Pozzato, C. Mazzaro, M. Crovatto et al., “Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia,” Blood, vol. 84, no. 9, pp. 3047–3053, 1994. View at Google Scholar · View at Scopus
  10. A. Mele, A. Pulsoni, E. Bianco et al., “Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study,” Blood, vol. 102, no. 3, pp. 996–999, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. A. S. Duberg, M. Nordström, A. Törner et al., “Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection,” Hepatology, vol. 41, no. 3, pp. 652–659, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. L. A. Anderson, R. Pfeiffer, J. L. Warren et al., “Hematopoietic malignancies associated with viral and alcoholic hepatitis,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 11, pp. 3069–3075, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. F. Marcucci and A. Mele, “Hepatitis viruses and non-Hodgkin's lymphoma: epidemiology, mechanism of tumorigenesis and therapeutic opportunities,” Blood, vol. 117, no. 6, pp. 1792–1798, 2011. View at Google Scholar
  14. L. A. Martyak, M. Yeganeh, and S. Saab, “Hepatitis C and lymphoproliferative disorders: from mixed cryoglobulinemia to non-Hodgkin's lymphoma,” Clinical Gastroenterology and Hepatology, vol. 7, no. 8, pp. 900–905, 2009. View at Publisher · View at Google Scholar · View at PubMed
  15. D. S. Viswanatha and A. Dogan, “Hepatitis C virus and lymphoma,” Journal of Clinical Pathology, vol. 60, no. 12, pp. 1378–1383, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. M. Ito, K. Murakami, T. Suzuki et al., “Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients,” Clinical Immunology, vol. 135, no. 3, pp. 459–465, 2010. View at Publisher · View at Google Scholar · View at PubMed
  17. D. Ennishi, Y. Maeda, N. Niitsu et al., “Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis,” Blood, vol. 116, no. 24, pp. 5119–5125, 2010. View at Publisher · View at Google Scholar · View at PubMed
  18. C. Visco, L. Arcaini, E. Brusamolino et al., “Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy,” Annals of Oncology, vol. 17, no. 9, pp. 1434–1440, 2006. View at Publisher · View at Google Scholar · View at PubMed
  19. C. Besson, D. Cantoni, E. Lepage et al., “Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 groupe d'etude des lymphomes de l'adulte programs,” Journal of Clinical Oncology, vol. 24, no. 6, pp. 953–960, 2006. View at Publisher · View at Google Scholar · View at PubMed
  20. O. Hermine, F. Lefrère, J. P. Bronowicki et al., “Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection,” New England Journal of Medicine, vol. 347, no. 2, pp. 89–94, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. D. Vallisa, P. Bernuzzi, L. Arcaini et al., “Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience,” Journal of Clinical Oncology, vol. 23, no. 3, pp. 468–473, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. V. La Mura, A. D. Renzo, F. Perna et al., “Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma,” Journal of Hepatology, vol. 49, no. 4, pp. 557–563, 2008. View at Publisher · View at Google Scholar · View at PubMed
  23. Y. Tsutsumi, Y. Yamamoto, J. Tanaka, N. Masauzi, M. Imamura, and M. Asaka, “Prevention of hepatitis B virus reactivation under rituximab therapy,” Immunotherapy, vol. 1, no. 6, pp. 1053–1061, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. V. Pitini, G. Sturniolo, C. Arrigo, S. Leonardi, S. Pino, and G. Altavilla, “HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy,” British Journal of Haematology, vol. 150, no. 1, pp. 108–127, 2010. View at Publisher · View at Google Scholar · View at PubMed